J Obes clinical study done in 2013
With 50 participants aged 18 and 65 years for 8 weeks and having a body mass index (BMI) ≥25 and ≤35, the primary outcomes included weight loss, while secondary outcomes included change in body composition and metabolic characteristics.
The study also monitored gastrointestinal tolerance and safety, recording symptoms and laboratory results for liver and kidney function.**
** Keithley JK, Swanson B, Mikolaitis SL, DeMeo M, Zeller JM, Fogg L, Adamji J. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. J Obes. 2013;2013:610908. doi: 10.1155/2013/610908. epub 2013 Dec 30. PMID: 24490058; PMCID: PMC3892933.